MUWRPs scientists and partners are part of a robust research program focused on cohort development, surveillance, and vaccine studies. MUWRP staff have presented posters and abstracts at international and national conferences on MUWRP’s various research activities around HIV and Ebola.
The MUWRP laboratory is committed to research and to promoting sustainability of research within the project by supporting young and early career scientists, which Uganda desperately needs. Additionally, it collaborates with MUJHU, IDI, UCLA and other local and international organizations. The program has expanded its portfolio to research into other communicable diseases of public health importance in Uganda.
HIV Research Studies
RV217 (ECHO): HIV-1 Prevalence, Incidence, Cohort Retention, and Host Genetics and Viral Diversity in High Risk Cohorts in East Africa.
HIV-V-A004 HIV Vaccine trial: a phase II study of an HIV candidate vaccine for prevention using Ad26 prime with MVA and protein boost.
Ebola/Marburg Vaccine Studies
In 2009, MUWRP and MHRP launched the first Ebola vaccine clinical trial conducted in Africa, using an early-generation DNA vaccine candidate developed by the Vaccine Research Center (VRC), RV247.
In 2015, MUWRP began a Phase 1b clinical trial of two experimental Ebola vaccines in Kampala, Uganda. The study uses Chimpanzee Adenovirus type 3 vector (ChAd3) vaccines, co-developed by the VRC, National Institutes of Allergy and Infectious Diseases (NIAID) and GlaxoSmithKine. The new study enrolled 90 participants and about 30 volunteers from the RV247 trial will receive a boost, or additional injection, of the cAd3-EBO vaccine to explore the more long-lasting effect of the vaccination.
MUWRP also conducted a long-term follow up study with the survivors of the 2007-08 Bundibugyo ebolavirus (BDBV) outbreak in Uganda. Results show that survivors experienced negative health effects that persisted more than two years after the outbreak claimed 39 lives.
Avian Influenza/Pandemic Influenza (GEIS)
MUWRP expanded its portfolio to include active surveillance of influenza and influenza-like viruses in humans, animals, and migratory birds in Uganda. The program developed an infrastructure and built capacity in clinical and immunological laboratory testing, data management, conducting clinical trials, and other related activities.
Additionally, MUWRP has renovated a laboratory at Bombo Military Hospital to enhance antimicrobial resistance work also under the GEIS program and enhance mil to mil operations, therefore providing additional diagnostic capabilities for clinicians and additional skills for the lab personnel.
Other Emerging Infections Research
A new program in 2016, Joint Mobile Emerging Disease Intervention Clinical Capability (JMEDICC) is creating a clinical research center of excellence able to deploy clinical trial capability into Ebola/Marburg outbreak settings in Uganda and in the region.
MUWRP also conducts sepsis research, supported by the Austere Environment Consortium for Enhanced Sepsis Outcomes (ACESO) expanded its portfolio to include active surveillance of influenza and influenza-like viruses in humans, animals, and migratory birds in Uganda. The program developed an infrastructure and built capacity in clin
Model for Community Engagement
MUWRP is committed to actively engaging communities throughout the research process, from trial protocol development/design through implementation to dissemination of research findings.
Through its community outreach component, MUWRP has engaged communities in Kampala and Kayunga districts by interfacing with the media, dialoguing with policymakers, sensitizing communities and their leaders to public health issues, orienting health professionals and most importantly, working with Community Advisory Boards.